BRAF and neoplasm: Thus, determining the frequency of the BRAF V600E allele from early access to a ctDNA sample might provide, in this latter specific context, a better-personalized treatment option than merely determining the BRAF mutation status in the tumor itself, and this to the benefit of better treatment efficacy.